Clinical value of tumour-associated antigens

A. MUNRO NEVILLE

From the Institute of Cancer Research, Royal Cancer Hospital, Chester Beatty Research Institute, London

Since the first clear demonstration of the existence of 'specific' antigens in experimental tumours (Gross, 1943; Foley, 1953), the extensive use of syngeneic animals has resulted in the identification of tumour-associated or characteristic macromolecules ('antigens') in association with spontaneously occurring or experimentally induced tumours (Old and Boyse, 1964; Baldwin, 1970; Stonehill and Bendich, 1970). Many different types of human tumour, including colonic (Gold and Freedman, 1965a), ovarian (Levi, Keller, and Mandl, 1969), bronchial (Yachi, Matsuura, Carpenter, and Hyde, 1968), mammary (Edynak, Hirshaut, Old, and Trempe, 1971; Fossati, Canevari, Della Porta, Balzarini, and Veronesi, 1972) and bladder carcinomas (Bubenik, Perlmann, Helmstein, and Moberger, 1970), neuroblastoma (Hellström, Hellström, Pierce, and Bill, 1968), melanoma (Morton, Malmgren, Holmes, and Ketcham, 1968; Jehn, Nathanson, Schwartz, and Skumen, 1970), lymphoma (Smith, Klein, Klein, and Clifford, 1968; Klein, Clifford, Henle, Henle, Geering, and Old, 1969; Buffé, Rimbaud, Lemerle, Schweiguth, and Burtin, 1970; Order, Porter, and Hellman, 1971), leukaemia (Harris et al, 1971; Halterman, Leventhal, and Mann, 1972), and sarcomas (Morton, Malmgren, Hall, and Schidlovsky, 1969; Wood and Morton, 1971) have also been shown to have tumour-associated antigens.

Of particular interest has been the finding that 'embryo or fetal associated antigens' can be present in association with human (Gold and Freedman, 1965a; Tee, Wang, and Watkins, 1965; Yachi et al, 1968; Häkkinen, and Viikari, 1969; Abelev, 1971; Mesa-Tejada, and Weiss, 1971; Trouillas, 1971) and animal tumours (Brawn, 1970; Coggin, Ambrose, and Anderson, 1970; Duff and Rapp, 1970; Baldwin, Glaives, and Vose, 1972) and that they could be released into the body fluids.

Possible Clinical Applications of Tumour-associated Antigens

The assay and identification of human tumour-associated antigens may promise new prospects in oncological medicine for the development of immunotherapeutic regimes and methods of detecting tumours together with their improved pathological classification.

One area of possible use lies in their facilitating tumour diagnosis, especially its earlier diagnosis and in improving clinical differentiation of neoplastic and non-neoplastic disorders. If successful therapy, such as surgical removal of the tumour, is associated with a return to normal levels of tumour-associated products in the body fluids, then their sequential assay during the follow-up phase may reveal rising titres which will enable recurrences to be detected earlier than by other clinical means. If therapy is instituted at that time, better survival rates may be achieved. Measurement of HCG levels in the plasma of patients with choriocarcinoma has proved to be a valuable aid in detecting residual tumour and in assessing the adequacy of therapeutic measures (Bagshawe, 1969). This line of investigation seems to be worthy of study using tumour-associated antigens as the index substances.

The detection of these antigens or their effects upon the immune system may have importance in the field of histopathology. At present, most tumours are classified histogenetically and behaviouristically, functional attributes, except for endocrine tumours, seldom being included. By outlining the tumour-associated antigens associated with a particular lesion, functional heterogeneity or homogeneity between tumours of identical or different morphology may be discerned which could have aetiological, behavioural, and prognostic significance.

In this communication, I will attempt to illustrate some of those aspects from our present knowledge of three tumour-associated antigens, namely, two oncofetal antigens, alpha-fetoprotein (AFP) (Abelev et al, 1963) and the carcinoembryonic antigen (CEA) (Gold and Freedman, 1965a and b), and the cancer basic protein (Carnegie, Caspary, and Field, 1972).

Sources and Chemical Aspects

ALPHA-FETOPROTEIN

This macromolecule was first described in the serum of neonatal mice and of adult mice bearing trans-
planteable hepatomas by Abelev et al (1963) and in patients with hepatocellular carcinomas, by Tata-
rinov (1965). Subsequent studies have shown AFP to be a single chain α1-globulin (molecular weight 64,000) containing 4% carbohydrate and which may exist in monomeric and dimeric forms (Nishi, 1970; Ruoslahti, Seppälä, Pikko, and Vuopio, 1971). Amino acid analyses have revealed that AFP and albumin are closely related proteins and that the alpha-fetoproteins extracted from fetal serum or from hepatomas are similar in amino acid composition (Nishi, 1970; Abelev, 1971; Ruoslahti et al, 1971).

Alpha-fetoprotein has been quantitated by different immunological techniques, including immunodiffusion (sensitivity of between 1 and 3 μg/ml serum), immunoadutoradiography (sensitivity, 50 ng/ml serum) (Abelev et al, 1971) and radioimmunoassay (sensitivity, 0.25 ng/ml serum) (Ruoslahti and Seppälä, 1971). It is formed principally by the fetal liver and also by the yolk sac and gastrointestinal tract (Gitlin and Boesman, 1967; Engelhardt, Shipova, Gusev, Yazova, and Ter-Grigorova, 1969; Gitlin and Pericelli, 1970; Gitlin, 1971). In the liver, most hepatocytes are initially involved in its synthesis by the sixth week of fetal life. The serum levels reach a peak, of the order of 3 to 4 mg/ml, about the thirteenth week of intrauterine life. Thereafter, the levels fall while albumin concentrations rise; these changes are paralleled by a decline in the number of AFP-forming hepatocytes which then tend to be concentrated around the central vein (Engelhardt et al, 1969). Small amounts of AFP continue to be formed by healthy adults, the detection of which requires radioimmunoassay; normal serum levels are below 10 ng/ml (Ruoslahti and Seppälä, 1971).

CARCINOEMBRYONIC ANTIGEN

In 1965, Gold and Freedman described the presence of a tumour antigen in primary adenocarcinomas of the human colon but not in autologous uninvolved colonic mucosa. It was also found in the embryonic gastrointestinal tract, liver, and pancreas during the first two trimesters of pregnancy and accordingly was called the carcinoembryonic antigen (Gold and Freedman, 1965a and b).

Detailed chemical studies of the structure of CEA are in progress and have already shown that it is a water-soluble glycoprotein with a molecular weight of approximately 200,000 and that it differs in its amino acid and carbohydrate composition from blood group substances (Krupey, Gold, and Freeman, 1967, 1968; Turberville, James, Darcy, Pelly, Johns, and Neville, 1973). Carcinoembryonic antigen is associated with the glycocalyx (cell coat) of the cell membrane and is detected in particular on the luminal aspect of neoplastic cells (von Kleist and Burtin, 1969). The development of sensitive radioimmunoassays for CEA (Thomson, Krupey, Freedman, and Gold, 1969; Lo Gerfo, Krupey, and Hansen, 1971; Egan, Lautenschleger, Coligan, and Todd, 1972) has shown that small amounts of CEA exist in some normal adult digestive tract tissues (Martin and Martin, 1970; Darcy, Turberville, and James, 1973) and that nanogram levels are detectable in the body fluids of healthy adults (Hall, Laurence, Darcy, Stevens, James, Roberts, and Neville, 1972; Laurence et al, 1972; Lo Gerfo, Herter, and Bennett, 1972).

CANCER BASIC PROTEIN

Field and Caspary (1970), using a macrophage electrophoretic mobility test, reported that the lymphocytes of patients with malignant tumours were sensitized to the encephalitogenic factor (EF). This cell-mediated immune phenomenon, also observed in patients suffering from destructive neurological disorders, led them to attempt the isolation of a macromolecule closely related to encephalitogenic factor from malignant tumours. A water-soluble basic protein with a molecular weight of approximately 16,000 has been identified in the plasma membrane of tumour cells (Carnegie et al, 1972). Like encephalitogenic factor, it contains a single tryptophan residue which is necessary for its antigenicity, but, using immunological and pharmacological methods, differences between encephalitogenic factor and the cancer basic protein are identifiable (Caspary and Field, 1971; Caspary, 1972; Field, Caspary, and Carnegie, 1971).

Role in the Diagnosis and Differential Diagnosis of Tumours

On presently available evidence, both AFP and CEA may have a part to play in association with particular tumours, whereas detection of lymphocyte sensitivity to the cancer basic protein is a phenomenon apparently characteristic of all malignant neoplasms. The results from two groups of workers using macrophage electrophoretic mobility test systems are shown in table I. The malignant tumours examined included a wide variety of epithelial neoplasms and lymphomas. Little overlap exists between the results of the control and malignant groups. Of the benign, inflammatory, or reactive conditions studied, only one example fell in the intermediate range and this patient gave a history of previous possible neurological damage (table I).

Positive results using this assay are obtained in patients with carcinomas in situ, those with advanced
Clinical value of tumour-associated antigens

<table>
<thead>
<tr>
<th>Authors</th>
<th>Condition</th>
<th>Percentage Reduction in Macrophage Mobility</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>&lt;5.0</td>
</tr>
<tr>
<td>Field and Caspary (1970)</td>
<td>Malignant tumours</td>
<td>79</td>
</tr>
<tr>
<td>Caspary (1972)</td>
<td>Fibroadenoma of breast</td>
<td>1*</td>
</tr>
<tr>
<td></td>
<td>Benign hypertrophy of prostate</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Chronic bronchitis</td>
<td>4</td>
</tr>
<tr>
<td>Pritchard et al (1972)</td>
<td>Controls</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Malignant tumour</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0</td>
</tr>
</tbody>
</table>

Table I Reduction in macrophage electrophoretic mobility in response to the encephalitogenic factor
1 All were laboratory workers exposed to nervous tissue antigens. This sensitization has not been observed by Pritchard et al (1972).
2 Widespread metastatic disease
3 Previous history of prolapsed vertebral disc
4 Patient gave history of sarcoidosis

Metastatic disease as well as patients treated successfully for carcinoma up to 24 years before testing (Field and Caspary, 1970).

Seven of the 154 patients of table I grouped under the heading of 'malignant tumours' did not have neoplasms at the time of the test; one has since developed a colonic carcinoma (Caspary, 1972). This ability of the test to detect precocious lymphocyte sensitivity before the tumour becomes clinically overt has also been revealed by finding positive reactions in children born many years before their mothers apparently developed clinically overt carcinomas (Field and Caspary, 1971b).

False negative results can arise because of radiotherapy, extensive metastatic disease, lymphatic leukaemia, and in those rare individuals who fail to exhibit any type of antigenic response (Field and Caspary, 1971a, 1972), whilst false positive reactions can occur in patients with a variety of disorders including sarcoidosis, tuberculosis, intrinsic asthma, rheumatoid arthritis, DLE, exposure to the influenza viruses, and destructive neurological disease.

If the initial promise is maintained after adequate follow up in the future of patients with inflammatory and regenerative disorders, benign tumours and precancerous conditions, detection of sensitivity to this basic protein may offer real assistance to early diagnosis and differential diagnosis.

At present, AFP is detected most commonly by gel diffusion methods and the expected incidence of positive assays and their value in tumour diagnosis can be seen in table II. With this technique, raised AFP levels are remarkably specific for hepatocellular carcinoma and malignant teratomas. Other carcinomas tend only to result in positive assays once they have metastasized to the liver (O'Conor, Tatarinov, Abelev, and Uriel, 1970; Alpert, Pin, and Isselbacher, 1971; Kozower, Fawaz, Miller, and Kaplan, 1971; Mehlman, Bulkley, and Wiernik, 1971).

Using the increased sensitivity of AFP radioimmunoassay, a less specific correlation with hepatomas and teratocarcinomas is seen. Patients with cirrhosis or viral hepatitis may also have significantly raised values. Nonetheless, radioimmunoassay gives a greater number (90-95%) of elevated AFP levels in patients with hepatocellular carcinoma. Some tumours, however, still fail to show appreciable amounts. This may be related in part to the host response. Hull, Carbone, Gitlin, O'Gara, and Kelly (1969) noted that the experimental liver tumours, induced in monkeys with nitrosodiethylamine, which possess a prominent lymphocytic infiltrate, are not associated with AFP formation. However, the round cell infiltrate disappears if and when AFP formation becomes manifest.

Whilst initial studies suggested that elevated plasma CEA levels were specific for endodermally derived carcinomas (Thomson et al, 1969), further experience has shown that raised plasma levels occur with a wide variety of non-neoplastic disorders and with neoplasms of widely differing histogenesis.
Gastrointestinal tract

<table>
<thead>
<tr>
<th>Site</th>
<th>Condition</th>
<th>Incidence of Positive Plasma CEA Assays (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy controls</td>
<td></td>
<td>5/556 (0.9)</td>
</tr>
<tr>
<td>Carcinoma of</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colon and rectum</td>
<td></td>
<td>272/386 (70)</td>
</tr>
<tr>
<td>Pancreas</td>
<td></td>
<td>57/62 (92)</td>
</tr>
<tr>
<td>Liver</td>
<td></td>
<td>12/18 (67)</td>
</tr>
<tr>
<td>Other sites</td>
<td></td>
<td>51/85 (60)</td>
</tr>
<tr>
<td>Diverticulitis, peptic ulceration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cirrhotic and alcoholic liver disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcoholic pancreatitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carcinoma</td>
<td></td>
<td>128/260 (49)</td>
</tr>
</tbody>
</table>

Breast

<table>
<thead>
<tr>
<th>Condition</th>
<th>Incidence of Positive Plasma CEA Assays (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benign tumour</td>
<td>1/30 (3)</td>
</tr>
<tr>
<td>Reactive-fibroadenosis</td>
<td>13/202 (6)</td>
</tr>
<tr>
<td>Carcinoma of bronchus</td>
<td>65/90 (72)</td>
</tr>
</tbody>
</table>

Respiratory tract

<table>
<thead>
<tr>
<th>Condition</th>
<th>Incidence of Positive Plasma CEA Assays (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary tuberculosis</td>
<td>8/21 (38)</td>
</tr>
<tr>
<td>Chronic bronchitis and emphysema</td>
<td>16/63 (25)</td>
</tr>
</tbody>
</table>

Table III  Preoperative plasma CEA levels in gastrointestinal, mammary, and respiratory disorders

1From the data of Moore et al (1971); Lo Gerfo et al (1971, 1972); Holyoke et al (1972); Laurence et al (1972); Reynoso et al (1972); and the author's further personal experience.

(Lo Gerfo et al, 1971; Moore, Kupchik, Marcon, and Zamchek, 1971; Laurence et al, 1972; MacSween, Warner, Bankhurst, and Mackay, 1972; Laurence and Neville, 1972; Reynoso et al, 1972; Zamchek, Moore, Dhar, and Kupchik, 1972). Of especial interest and potential clinical importance has been the finding of raised CEA levels in the urine of patients with urothelial carcinoma (Hall et al, 1972).

The assay of plasma CEA seems to have most clinical application in the diagnosis of carcinomas of the gastrointestinal tract, pancreas, and bronchus, approximately 70-92% of which will yield raised values (table III). It is also of value in the assessment of neuroblastoma (Reynoso et al, 1972) and possibly mammary carcinoma (table III) but has little or no part to play in the diagnosis of tumours at other sites (Laurence et al, 1972).

The component cell types of tumours or the degree of their structural differentiation do not seem to influence the level of plasma CEA (Laurence et al, 1972). This is determined more by the extent of tumour spread (table IV).

Using the assay of Egan et al (1972), it is possible to divide the plasma CEA levels into three groups, namely, normal (<12.5 ng/ml), intermediate (12.5-40 ng/ml), and high (>40 ng/ml) (Laurence and Neville, 1972). Whilst patients with benign and malignant tumours and with inflammatory or regenerative disorders may fall into either the normal or intermediate groups, levels in excess of 40 ng/ml are nearly always diagnostic of a malignant tumour (Laurence et al, 1972). Although 30% of mammary, 41% of colonic, and 60% of bronchial carcinomas, which are still localized at the time of surgery, yield intermediate or high values, only 8%, 12%, and 17% respectively of such early tumours give levels in the 'cancer' diagnostic range (>40 ng/ml) (Laurence et al, 1972). Thus, the detection rate of even earlier lesions may be less, making plasma CEA estimation of little or no value as a screening procedure.

Since the urinary bladder is also an entodermally derived structure, it was thought that CEA might
Clinical value of tumour-associated antigens

Table VI Urinary CEA levels in male patients as a function of the stage and growth of transitional cell carcinomas

<table>
<thead>
<tr>
<th>Stage</th>
<th>Urinary CEA (ng/ml)</th>
<th>Grade</th>
<th>Urinary CEA (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;35</td>
<td>55-60</td>
<td>61-100</td>
</tr>
<tr>
<td>T1</td>
<td>5</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>T2</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>T3</td>
<td>3</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>T4</td>
<td>2</td>
<td>1</td>
<td>—</td>
</tr>
</tbody>
</table>

1 UICC classification.
2 The histology of eight tumours was not available for personal review and those have been omitted.

Role in Management of Patients in Follow-up Phase

The aspect of plasma CEA estimations which is attracting most current attention is its role in the detection of residual neoplastic disease and in the development of metastases. If the plasma CEA is raised preoperatively, complete tumour removal is associated with a decline to normal levels between the second and eighteenth postoperative days; a remaining high level indicates residual disease (Dhar, Moore, Zamchek, and Kupchick, 1972; Holyoke, Reynoso, and Chu, 1972; Laurence et al, 1972). We are at present examining a large group of patients in the follow-up phase after surgical treatment for colorectal carcinoma and our experience to date, and that of Dhar et al (1972), indicate that the development of recurrent and/or metastatic disease is most often associated with a rise of CEA to pathological levels. Moreover, such a rise can occur in advance of clinically detectable tumour (fig).

Plasma CEA levels are raised in only a minority of patients with localized bladder carcinomas, but with extravasal or pelvic spread, the incidence of raised values increases (table IV). Hence, the estimation

occur in the urine of patients with urothelial carcinomas. Preliminary work has confirmed this hypothesis (Hall et al, 1972; table IV). Sixty-eight per cent of patients with proved urothelial carcinomas have raised urinary CEA values which return to normal when the tumour is successfully removed. Urinary CEA levels are normal in association with non-urothelial tumours, such as hypernephroma and prostatic carcinoma, even when plasma levels are raised. Only when such tumours involve the urinary tract by infiltration, do the urine levels rise. Accordingly, elevated urinary CEA levels are specific to urothelial carcinomas provided urinary infection can be excluded (Hall et al, 1972; table V).

The degree of structural tumour differentiation does not influence the level of urinary CEA (Hall et al, 1972) and high levels occur with all stages of the disease (table VI). Thus, it can be seen that well differentiated tumours in situ, which are difficult to detect by urinary exfoliative cytology, may be associated with raised levels. Consequently, urinary CEA assays could be important in the screening of high-risk population groups such as those in the rubber or dye industries.
of both the urinary and plasma CEA in the follow-up phase after treatment may be of value in facilitating the detection of local and distant recurrences of urothelial carcinomas.

Little attention has been paid to this aspect of the clinical role of AFP assays. However, there is evidence in animals and man to suggest that the development of hepatomas may be preceded by rises in AFP serum levels and that recurrences are associated with coincident rises in AFP values to reach previous or even higher levels (Houštěk, Masopust, Kithier, and Rádl, 1968; Hull, Carbone, Gitlin, O’Gara, and Kelly, 1969; Mawas, Kohen, Lemele, Buffé, Schweiguth, and Burtin, 1969; Khazanov, Abelev, Perova, Polenko, Ryapsova, and Shirenkova, 1971; Watabe, 1971; Braunstein, Bridson, Glass, Hull, and McIntire, 1972; McIntire, Vogel, Princler, and Patel, 1972).

Role in Assessing the Effects of Therapy

Both AFP and CEA have been employed as biochemical index substances to assess the effects of chemotherapy.

Successful therapy, including chemotherapy for hepatocarcinoma and teratocarcinoma, is associated with a decline in AFP levels which rise again with the development of recurrences (Mawas et al., 1969). Clinical improvement may be matched by falls in AFP levels but in several patients a decline in AFP values was not accompanied by any clinical response (Purves, Bersohn, and Geddes, 1970).

Holyoke and his associates (1972) have employed plasma CEA levels to monitor the effectiveness of chemotherapy. They reported that a favourable clinical response with a marked decrease in tumour size was associated with a decline of the CEA levels in plasma to normal. Relapse subsequently occurred and was preceded by a rise of CEA levels to pathological levels. These interesting observations need further study, but are of potential importance to the chemotherapist and radiotherapist.

A recent example of a hepatoblastoma secreting both HCG and AFP emphasizes the importance of trying to measure as many biochemical indices as possible for every tumour. Braunstein et al (1972) noted discordance between HCG and AFP levels in response to chemotherapy. These discrepancies suggest that different cell lines in the same tumour may display differential responses.

Role in Assessing Prognosis

Mawas et al (1969) have commented that patients with raised AFP levels have more aggressive teratocarcinomas whilst the majority of AFP-negative malignant teratomas respond to therapy. This may represent a valuable prognostic aid in assessing tumours which may appear to be equally ‘malignant’ on morphological grounds. This relationship does not appear to be the case in patients with hepatomas where the levels seem to be independent of tumour size, stage, or differentiation (Purves, Macnab, and Bersohn, 1968).

It is not yet known if patients with localized tumours and high CEA levels in the plasma or urine pursue a better or worse course than those whose tumours are associated with normal CEA values. Recent experimental evidence suggests the possible importance of ascertaining this point. Kim and Carruthers (1972) examined two strains of experimental breast carcinoma which differed in their metastasizing potential. They found an inverse relationship between the presence of an antigen not necessarily CEA in the glycocalyx of the tumour cells and its concentration in serum. As the surface glycoprotein declined in amount and level in plasma rose, the metastasizing potential increased.

Conclusions and Prospects

The presence of tumour-associated macromolecules in association with human tumours is now well established. They occur within or on the cell surface and may be released into the body fluids. Many are also known to be present in fetal tissues and some possess biological activity (Laurence and Neville, 1972).

Numerous further tumour-associated antigens will almost certainly be identified in the next few years, and it is imperative that the relationship of one
Clinical value of tumour-associated antigens

material to another and their possible role in clinical practice are examined in an integrated and meaningful manner.

None of the presently recognized tumour-associated principles are specific for malignant tumours, quantitative rather than qualitative differences exist among inflammatory disorders, benign and malignant tumours. Nonetheless, such materials have a clinical role at this time, assisting in tumour diagnosis and monitoring the effects of therapy.

It seems worthwhile in the future to attempt to measure as many as possible of the known tumour-associated principles including the ‘ectopic’ hormones. In this way, a battery of tests will be available which, when viewed together, may improve tumour detection and its differential diagnosis. Finally, by outlining such spectra, functional heterogeneity between tumours of identical light morphology or between cells of the same tumour may be observed which could have behaviouristic, histogenetic, and aetiological significance.

References


Clinical value of tumour-associated antigens

A. Munro Neville

J Clin Pathol 1974 s3-7: 119-126
doi: 10.1136/jcp.s3-7.1.119

Updated information and services can be found at:
http://jcp.bmj.com/content/s3-7/1/119.citation

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/